Bidding war for Stada Arz intensifies, with third offer

20 February 2017

German generic drugmaker Stada Arzneimittel (SAZ: Xetra) has confirmed receipt of another – third - legally non-binding conditional expression of interest regarding a bid for the acquisition of up to 100% of the shares in the company at an indicative takeover price of 58.00 euros per Stada share, or about 3.61 billion euros ($3.84 billion).

While Stada itself did not identify the name of the latest bidder, according to a report by Bloomberg, citing ‘people familiar with the matter,’ it is Bain Capital

Last week, Stada revealed it had received a bid from private equity firm Cinven Partners of 56.00 euros per share, and subsequently confirmed an approach from Advent International Corp, but did not reveal any offer price.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK